GlaxoSmithKline (GSK) and Nabi Biopharmaceuticals (NABI) signed a licensing agreement for a nicotine conjugate vaccine (NicVAX) as well as for the development of a second generation nicotine vaccine. NicVAX is an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse. Earlier in October, the vaccine received a $10 million grant from the National Institute on Drug Abuse.

As per the agreement, Nabi will get an upfront payment of $40 million and is eligible to receive more than $500 million (together with upfront payment) as option fees and milestones for the vaccine, NicVAX, and follow-on nicotine vaccines. Nabi has the potential to receive double-digit royalties from sales if the product is commercialized. GlaxoSmithKline will have an option to exclusively in-license NicVAX on a worldwide basis and a license to develop follow-on next-generation nicotine vaccines using Nabi's intellectual property together with GSK's own technology.

NicVAX is currently

...

TapImmune Inc. is a biotechnology company headquartered in Bellevue, Washington. They specialize in the development of immunotherapeutic vaccines for cancer and infectious diseases. Their core business focus is on emerging technologies based on cellular immunology and genetic understanding of the cause and potential novel treatments of disease.

TapImmune Inc.’s lead product is the TAP vaccine. It performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers. Therefore, the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. In addition, the TAP molecule works as an adjuvant (accelerant) to enhance targeted vaccines against infectious diseases.

The Company is developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The expectation is that the global vaccine market will grow from $13 billion in 2007 to $21 billion

...

Enzo Biochem Inc. (NYSE:ENZ) announced today that they have favorable results of the Company’s clinical trial for the treatment of non-alcoholic steatohepatitis. The information was presented by Enzo Biochem at the annual meeting of the American Association for the Study of Liver Diseases. Currently, the causes of NASH are not well-defined due to which there is currently no medical therapy available in the market to combat NASH.

Enzo Biochem is one of the leading biopharmaceuticals companies that is into research and development, manufacturing, licensing of innovative healthcare products and technologies based on molecular biology and genetic engineering techniques. Currently, the Company has around forty thousand products that serve under molecular biology, drug discovery, and pathology research markets. Enzo’s scientists and collaborators have presented the data that showed that oral administration of EGS21 is safe and remains biologically active in the patients with insulin resistance and NASH which leads to the

...

Geron Corporation (NASDAQ:GERN) today announced that they have reached an agreements with the Food and Drug Administration to re-initiate clinical trials for spinal cord injury. The company said that they plan to advance clinical development of their human embryonic stem cell (hESC)-based product, GRNOPC1 which will be used for the treatment of spinal cord injuries. The plan is to let Geron Corporation restart the Phase 1 clinical trial of GRNOPC1 in patients who are suffering from complete thoracic spinal cord injury and to support the future expansion of the clinical trial with patients who are suffering from cervical injuries.

Geron Corporation is one of the developers for the first-in-class biopharmaceuticals that is used for the treatment of cancer and chronic degenerative diseases like spinal cord injury, diabetes and heart failure. GRNOPC1 that is being developed by Geron Corporation is made for the treatment of spinal cord injury but Geron is

...

Pall Corporation (PLL) saw quarter over quarter sales growth in its fiscal fourth quarter as it surprised on the Zacks Consensus Estimate by 9.62%. Even with the financial crisis, Pall raised its dividend in fiscal 2009.

Company Description

Pall designs solutions in filtration, separation and purification for customers across a wide range of industries including biopharmaceutical, hospital and transfusion medicine, energy and alternative energy, electronics, municipal and industrial water, aerospace, and transportation.

The company's Total Fluid Management solutions enable customers to minimize emissions and waste.

Pall Saw Economic Conditions Improving

On Sep 14, the company reported fiscal fourth quarter 2009 earnings and full-year 2009 earnings. Revenues in the fourth quarter were still off 2008 levels but some segments saw improvement.

Life Sciences' sales rose 5.2%, Medical sales grew 1.6%, and Biopharmaceuticals climbed 7.8%. But the Industrial Segment struggled, declining 8.8% year over year which reflects the state of the

...

Nutra Pharma Corp.

(Public, OTC:NPHC)

Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma’s stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within the next 12 months. The company has recently made waves throughout the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, and was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. Winning this was no easy task, as a handful of well known companies attended the conference. The

...

DrStockPick.com Stock Report!

Friday August 28, 2009

**************************************************************

Muscle Flex Inc. (PINKSHEETS: MFLI) announced today that Danny Alex, CEO of Muscle Flex Inc. (www.MuscleFlexInc.com), has been exclusively invited to the WWDMAGIC (www.MagicOnline.com) fashion tradeshow in Las Vegas by Houston PAD (www.HoustonProjects.com), Master Distributor of VATA Brasil Active Wear (www.VataBrasil.com). The invitation to attend WWDMAGIC comes as Muscle Flex Inc. is preparing to add its Muscle Flex® sports and active wear product line as one of its flagship products. Additional details are expected in the coming days.

Legend International Holdings, Inc (OTCBB:LGDI) is pleased to announce that the Queensland Government has granted the Exploration Permit for Paradise

...

ZymoGenetics, Inc. (ZGEN) has filed a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA) requesting the agency to remove King Pharmaceuticals’ (KG) Thrombin-JMI from the market in the interest of patient safety. ZymoGenetics filed the CP based on reports of serious or fatal bleeding-related adverse events in surgical patients exposed to bovine (cattle-derived) thrombin. Thrombin-JMI is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible. The source material for Thrombin-JMI comes from bovine plasma and lung tissue. The treatment is a key product in King’s portfolio. For the twelve months ended December 31, 2008, Thrombin-JMI accounted for 16.3% of total revenues. As such, the removal of the product from the market would be a major blow for the company. Thrombin-JMI revenues have been under pressure lately due to the entry ...

I recently highlighted a small biotech firm, ISIS Pharmaceuticals, as a potential “value” growth play. ISIS took a tumble after earnings despite being just a penny off of estimates. Despite slightly lower than expected earnings, the Company showed a strong cash position, moderate cash burn, and a likelihood that it would be able to at least make it through full trials for its most promising drug. I know that for some even this doesn’t count as value. Afterall, the Company is not free cash positive and any value ascribed to the Company is derived from future expectations of its drug pipeline of which there are none currently in distribution.

For those looking for more proven business models but still looking to take advantage of the coming shift towards genetic pharmaceuticals as opposed to small molecule pharmaceuticals, a look at ISIS’s partners may clue you into some

...

For Immediate Release

Chicago, IL – August 7, 2009 – Zacks Equity Research highlights Baxter International (BAX) as the Bull of the Day and The Corporate Executive Board (EXBD) the Bear of the Day. In addition, Zacks Equity Research provides analysis on King Pharmaceuticals, Inc. (KG), ZymoGenetics (ZGEN) and Cephalon (CEPH).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676

Here is a synopsis of all five stocks:

Bull of the Day:

We believe that Baxter International’s (BAX) focus on life-sustaining products insulates its results from the current economic downturn and provide investors with good quality returns on a risk-adjusted basis.

The company has a strong product pipeline, with a number of promising products in the final stages of clinical trials. Baxter's strong market position is demonstrated in its recent quarterly performance that came ahead of guidance, while earnings exceeded

...